Table 2.
Fine mapping of demyelination region of IL-2 using synthetic peptidesa
| Peptide injectedb | Demyelination |
||
|---|---|---|---|
| Brain | SC | ON | |
| Full-length IL-2 protein | Yes | Yes | Yes |
| Peptides 1–10 | Yes | Yes | Yes |
| Peptides 11–21 | No | No | No |
| Peptides 22–32 | No | No | No |
| Peptide 1 (MYSMQLASCVTLTLV) | No | No | No |
| Peptide 2 (LASCVTLTLVLLVNS) | No | No | No |
| Peptide 3 (TLTLVLLVNSAPTSS) | No | No | No |
| Peptide 4 (LLVNSAPTSSSTSSS) | Yes | Yes | Yes |
| Peptide 5 (APTSSSTSSSTAEAQ) | Yes | Yes | Yes |
| Peptide 6 (STSSSTAEAQQQQQQ) | Yes | Yes | Yes |
| Peptide 7 (TAEAQQQQQQQQQQQ) | No | No | No |
| Peptide 8 (QQQQQQQQQQQHLEQ) | No | No | No |
| Peptides 7–32 | No | No | No |
a
C57BL/6 mice were injected with 10 μg of each peptide at 7 days and 4 h before ocular infection with HSV-1 strain McKrae. The first injection included CFA, and the second injection included IFA. Demyelination was assessed at 14 days p.i.
b
Boldface amino acids indicate areas of overlap between the peptides.